{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:19:39Z","timestamp":1780391979039,"version":"3.54.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-025-03322-1","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:42:36Z","timestamp":1772581356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7308-6253","authenticated-orcid":false,"given":"Mural","family":"Quadros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6638-5562","authenticated-orcid":false,"given":"Naveen","family":"Rajana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3618-8178","authenticated-orcid":false,"given":"Vivek","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"3322_CR1","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(24)00111-5","volume":"12","author":"KG Blyth","year":"2024","unstructured":"Blyth KG, Adusumilli PS, Astoul P, Darlison L, Lee YCG, Mansfield AS, et al. Leveraging the pleural space for anticancer therapies in pleural mesothelioma. Lancet Respir Med. 2024;12:476\u201383. https:\/\/doi.org\/10.1016\/S2213-2600(24)00111-5.","journal-title":"Lancet Respir Med"},{"key":"3322_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69:402\u201329. https:\/\/doi.org\/10.3322\/caac.21572.","journal-title":"CA Cancer J Clin"},{"key":"3322_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","volume":"33","author":"S Popat","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2022;33:129\u201342. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.005.","journal-title":"Ann Oncol"},{"key":"3322_CR4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMra1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385:1207\u201318. https:\/\/doi.org\/10.1056\/NEJMra1912719.","journal-title":"N Engl J Med"},{"key":"3322_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155432","volume":"21","author":"S Burgio","year":"2020","unstructured":"Burgio S, Noori L, Marino Gammazza A, Campanella C, Logozzi M, Fais S, et al. Extracellular vesicles-based drug delivery systems: a new challenge and the exemplum of malignant pleural mesothelioma. Int J Mol Sci. 2020;21:5432. https:\/\/doi.org\/10.3390\/ijms21155432.","journal-title":"Int J Mol Sci"},{"key":"3322_CR6","doi-asserted-by":"publisher","unstructured":"Yilmaz ME, Rashidfarokhi M, Pollard K, Durmus N, Keserci S, Sterman DH, Arslan AA, Shao Y, Reibman J. Mesothelioma Cases in the World Trade Center Survivors, Ann Case Rep. 2024;9.\u00a0https:\/\/doi.org\/10.29011\/2574-7754.101709. https:\/\/doi.org\/10.29011\/2574-7754.101709.","DOI":"10.29011\/2574-7754.101709"},{"key":"3322_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245808","volume":"15","author":"B Bertin","year":"2023","unstructured":"Bertin B, Zugman M, Schvartsman G. The current treatment landscape of malignant pleural mesothelioma and future directions. Cancers (Basel). 2023;15:5808. https:\/\/doi.org\/10.3390\/cancers15245808.","journal-title":"Cancers (Basel)"},{"key":"3322_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/JCO.21.01567","volume":"40","author":"AS Tsao","year":"2022","unstructured":"Tsao AS, Pass HI, Rimner A, Mansfield AS. New era for malignant pleural mesothelioma: updates on therapeutic options. J Clin Oncol. 2022;40:681\u201392. https:\/\/doi.org\/10.1200\/JCO.21.01567.","journal-title":"J Clin Oncol"},{"key":"3322_CR9","unstructured":"C. for D.E. and Research, FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma, FDA. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-unresectable-advanced-or-metastatic. Accessed 18 Feb 2025."},{"key":"3322_CR10","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.21037\/tlcr-20-673","volume":"10","author":"J Menis","year":"2021","unstructured":"Menis J, Pasello G, Remon J. Immunotherapy in malignant pleural mesothelioma: a review of literature data. Transl Lung Cancer Res. 2021;10:2988\u20133000. https:\/\/doi.org\/10.21037\/tlcr-20-673.","journal-title":"Transl Lung Cancer Res"},{"key":"3322_CR11","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","volume":"22","author":"C Pinto","year":"2021","unstructured":"Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021;22:1438\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(21)00404-6.","journal-title":"Lancet Oncol"},{"key":"3322_CR12","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344. https:\/\/doi.org\/10.1200\/JCO.2003.11.136.","journal-title":"J Clin Oncol"},{"key":"3322_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176306","volume":"21","author":"NS Kulkarni","year":"2020","unstructured":"Kulkarni NS, Vaidya B, Parvathaneni V, Bhanja D, Gupta V. Repurposing quinacrine for treatment of malignant mesothelioma: in-vitro therapeutic and mechanistic evaluation. Int J Mol Sci. 2020;21:6306. https:\/\/doi.org\/10.3390\/ijms21176306.","journal-title":"Int J Mol Sci"},{"key":"3322_CR14","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","volume":"24","author":"V Parvathaneni","year":"2019","unstructured":"Parvathaneni V, Kulkarni NS, Muth A, Gupta V. Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov Today. 2019;24:2076\u201385. https:\/\/doi.org\/10.1016\/j.drudis.2019.06.014.","journal-title":"Drug Discov Today"},{"key":"3322_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/2162-3619-1-27","volume":"1","author":"T Latif","year":"2012","unstructured":"Latif T, Chauhan N, Khan R, Moran A, Usmani SZ. Thalidomide and its analogues in the treatment of multiple myeloma. Exp Hematol Oncol. 2012;1:27. https:\/\/doi.org\/10.1186\/2162-3619-1-27.","journal-title":"Exp Hematol Oncol"},{"key":"3322_CR16","unstructured":"R. Brazil, Repurposing Viagra: the \u2018little blue pill\u2019 for all ills?. Pharml J. 2018. https:\/\/pharmaceutical-journal.com\/article\/feature\/repurposing-viagra-the-little-blue-pill-for-all-ills. Accessed 19 Feb 2025."},{"key":"3322_CR17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","volume":"6","author":"M Brevet","year":"2011","unstructured":"Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB, et al. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol. 2011;6:864\u201374. https:\/\/doi.org\/10.1097\/JTO.0b013e318215a07d.","journal-title":"J Thorac Oncol"},{"key":"3322_CR18","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/aps.2017.5","volume":"38","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Zheng B, Wang H, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38:614\u201322. https:\/\/doi.org\/10.1038\/aps.2017.5.","journal-title":"Acta Pharmacol Sin"},{"key":"3322_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24020","volume":"24","author":"N Fleeman","year":"2020","unstructured":"Fleeman N, Houten R, Bagust A, Richardson M, Beale S, Boland A, et al. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. Health Technol Assess. 2020;24:1\u2013180. https:\/\/doi.org\/10.3310\/hta24020.","journal-title":"Health Technol Assess"},{"key":"3322_CR20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3978\/j.issn.2218-6751.2015.03.06","volume":"4","author":"JC Chuang","year":"2015","unstructured":"Chuang JC, Neal JW. Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. Transl Lung Cancer Res. 2015;4:639\u201341. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2015.03.06.","journal-title":"Transl Lung Cancer Res"},{"key":"3322_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26920","author":"T-M Theilen","year":"2018","unstructured":"Theilen T-M, Soerensen J, Bochennek K, Becker M, Schwabe D, Rolle U, et al. Crizotinib in ALK+ inflammatory myofibroblastic tumors-current experience and future perspectives. Pediatr Blood Cancer. 2018. https:\/\/doi.org\/10.1002\/pbc.26920.","journal-title":"Pediatr Blood Cancer"},{"key":"3322_CR22","doi-asserted-by":"publisher","unstructured":"Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005;11:2300\u20134. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1940.","DOI":"10.1158\/1078-0432.CCR-04-1940"},{"key":"3322_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","volume":"51","author":"A Destro","year":"2006","unstructured":"Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, et al. EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer. 2006;51:207\u201315. https:\/\/doi.org\/10.1016\/j.lungcan.2005.10.016.","journal-title":"Lung Cancer"},{"key":"3322_CR24","doi-asserted-by":"publisher","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","volume":"29","author":"J Remon","year":"2018","unstructured":"Remon J, Steuer CE, Ramalingam SS, Felip E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol. 2018;29:i20\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdx704.","journal-title":"Ann Oncol"},{"key":"3322_CR25","doi-asserted-by":"publisher","unstructured":"Priantti JN, Fujiwara Y, Aquino de Moraes FC, Michelon I, Castro C, Leighl NB, Cavalcante L, Addeo A, Bar J, Horita N, Cortellini A, Nassar AH, Vilbert M, Naqash AR. Safety and Efficacy of Osimertinib in Patients With Non\u2013Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis, JCO Precis Oncol. 2024;e2400331. https:\/\/doi.org\/10.1200\/PO.24.00331.","DOI":"10.1200\/PO.24.00331"},{"key":"3322_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221103212","volume":"14","author":"BC Agema","year":"2022","unstructured":"Agema BC, Veerman GDM, Steendam CMJ, Lanser DAC, Preijers T, van der Leest C, et al. Improving the tolerability of osimertinib by identifying its toxic limit. Ther Adv Med Oncol. 2022;14:17588359221103212. https:\/\/doi.org\/10.1177\/17588359221103212.","journal-title":"Ther Adv Med Oncol"},{"key":"3322_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054333","volume":"24","author":"X Guo","year":"2023","unstructured":"Guo X, Zuo X, Zhou Z, Gu Y, Zheng H, Wang X, et al. PLGA-based micro\/nanoparticles: an overview of their applications in respiratory diseases. Int J Mol Sci. 2023;24:4333. https:\/\/doi.org\/10.3390\/ijms24054333.","journal-title":"Int J Mol Sci"},{"key":"3322_CR28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1208\/s12249-023-02712-7","volume":"24","author":"YH Dinakar","year":"2023","unstructured":"Dinakar YH, Rajana N, Kumari NU, Jain V, Mehra NK. Recent advances of multifunctional PLGA nanocarriers in the management of triple-negative breast cancer. AAPS PharmSciTech. 2023;24:258. https:\/\/doi.org\/10.1208\/s12249-023-02712-7.","journal-title":"AAPS PharmSciTech"},{"key":"3322_CR29","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.3390\/pharmaceutics14122728","volume":"14","author":"HO Alsaab","year":"2022","unstructured":"Alsaab HO, Alharbi FD, Alhibs AS, Alanazi NB, Alshehri BY, Saleh MA, et al. PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases. Pharmaceutics. 2022;14:2728. https:\/\/doi.org\/10.3390\/pharmaceutics14122728.","journal-title":"Pharmaceutics"},{"key":"3322_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1208\/s12248-021-00611-y","volume":"23","author":"Y Wang","year":"2021","unstructured":"Wang Y, Qin B, Xia G, Choi SH. FDA\u2019s poly (lactic-co-glycolic acid) research program and regulatory outcomes. AAPS J. 2021;23:92. https:\/\/doi.org\/10.1208\/s12248-021-00611-y.","journal-title":"AAPS J"},{"key":"3322_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12249-023-02502-1","volume":"24","author":"R Mahar","year":"2023","unstructured":"Mahar R, Chakraborty A, Nainwal N, Bahuguna R, Sajwan M, Jakhmola V. Application of PLGA as a biodegradable and biocompatible polymer for pulmonary delivery of drugs. AAPS PharmSciTech. 2023;24:39. https:\/\/doi.org\/10.1208\/s12249-023-02502-1.","journal-title":"AAPS PharmSciTech"},{"key":"3322_CR32","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.3390\/ijms24065204","volume":"24","author":"X Wang","year":"2023","unstructured":"Wang X, Chauhan G, Tacderas ARL, Muth A, Gupta V. Surface-modified inhaled microparticle-encapsulated Celastrol for enhanced efficacy in malignant pleural mesothelioma. Int J Mol Sci. 2023;24:5204. https:\/\/doi.org\/10.3390\/ijms24065204.","journal-title":"Int J Mol Sci"},{"key":"3322_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17040470","volume":"17","author":"S Nana","year":"2025","unstructured":"Nana S, Govender M, Choonara YE. Modified-release pulmonary delivery systems for labile bioactives: design, development, and applications. Pharmaceutics. 2025;17:470. https:\/\/doi.org\/10.3390\/pharmaceutics17040470.","journal-title":"Pharmaceutics"},{"key":"3322_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.131491","volume":"267","author":"DG Gadhave","year":"2024","unstructured":"Gadhave DG, Quadros M, Ugale AR, Goyal M, Ayehunie S, Gupta V. Mucoadhesive chitosan-poly (lactic-co-glycolic acid) nanoparticles for intranasal delivery of quetiapine \u2013 development & characterization in physiologically relevant 3D tissue models. Int J Biol Macromol. 2024;267:131491. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.131491.","journal-title":"Int J Biol Macromol"},{"key":"3322_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2024.214027","volume":"166","author":"G Chauhan","year":"2025","unstructured":"Chauhan G, Shaik AA, Sawant SS, Diwan R, Mokashi M, Goyal M, et al. Continuously producible aztreonam-loaded inhalable lipid nanoparticles for cystic fibrosis-associated Pseudomonas aeruginosa infections \u2013 development and in-vitro characterization. Biomaterials Advances. 2025;166:214027. https:\/\/doi.org\/10.1016\/j.bioadv.2024.214027.","journal-title":"Biomaterials Advances"},{"key":"3322_CR36","doi-asserted-by":"crossref","unstructured":"Systematic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment, (n.d.). https:\/\/www.mdpi.com\/1999-4923\/12\/3\/206. Accessed 19 Nov 2025.","DOI":"10.3390\/pharmaceutics12030206"},{"key":"3322_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.14227\/DT180311P15","volume":"18","author":"MRC Marques","year":"2011","unstructured":"Marques MRC, Loebenberg R, Almukainzi M. Simulated biological fluids with possible application in dissolution testing. Dissolution Technol. 2011;18:15\u201328. https:\/\/doi.org\/10.14227\/DT180311P15.","journal-title":"Dissolution Technol"},{"key":"3322_CR38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/pharmaceutics11110559","volume":"11","author":"SK Shukla","year":"2019","unstructured":"Shukla SK, Kulkarni NS, Chan A, Parvathaneni V, Farrales P, Muth A, et al. Metformin-encapsulated liposome delivery system: an effective treatment approach against breast cancer. Pharmaceutics. 2019;11:559. https:\/\/doi.org\/10.3390\/pharmaceutics11110559.","journal-title":"Pharmaceutics"},{"key":"3322_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.132526","volume":"271","author":"G Chauhan","year":"2024","unstructured":"Chauhan G, Wang X, Quadros M, Vats M, Gupta V. Chitosan\/bovine serum albumin layer-by-layer assembled particles for non-invasive inhaled drug delivery to the lungs. Int J Biol Macromol. 2024;271:132526. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.132526.","journal-title":"Int J Biol Macromol"},{"key":"3322_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/17425247.2019.1598374","volume":"16","author":"PL Chia","year":"2019","unstructured":"Chia PL, Scott AM, John T. Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma. Expert Opin Drug Deliv. 2019;16:441\u201351. https:\/\/doi.org\/10.1080\/17425247.2019.1598374.","journal-title":"Expert Opin Drug Deliv"},{"key":"3322_CR41","doi-asserted-by":"publisher","unstructured":"R G, Ra K, Je H, Ga N, R V, D W, Mr G, Hl K. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res\u202f: An Off J Am Assoc Cancer Res. 2005;11. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1940.","DOI":"10.1158\/1078-0432.CCR-04-1940"},{"key":"3322_CR42","doi-asserted-by":"publisher","first-page":"9928","DOI":"10.1038\/s41598-020-66644-z","volume":"10","author":"K-I Lee","year":"2020","unstructured":"Lee K-I, Su C-C, Fang K-M, Wu C-C, Wu C-T, Chen Y-W. Ultrafine silicon dioxide nanoparticles cause lung epithelial cells apoptosis via oxidative stress-activated PI3K\/Akt-mediated mitochondria- and endoplasmic reticulum stress-dependent signaling pathways. Sci Rep. 2020;10:9928. https:\/\/doi.org\/10.1038\/s41598-020-66644-z.","journal-title":"Sci Rep"},{"key":"3322_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.844924","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Li X, Zhang H, Yan M, Jia M, Zhou Q. A transcriptome sequencing study on genome-wide gene expression differences of lung cancer cells modulated by fucoidan. Front Bioeng Biotechnol. 2022. https:\/\/doi.org\/10.3389\/fbioe.2022.844924.","journal-title":"Front Bioeng Biotechnol"},{"key":"3322_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120843","volume":"306","author":"V Parvathaneni","year":"2022","unstructured":"Parvathaneni V, Chilamakuri R, Kulkarni NS, Wang X, Agarwal S, Gupta V. Repurposing clofazimine for malignant pleural mesothelioma treatment \u2014 in-vitro assessment of efficacy and mechanism of action. Life Sci. 2022;306:120843. https:\/\/doi.org\/10.1016\/j.lfs.2022.120843.","journal-title":"Life Sci"},{"key":"3322_CR45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/pharmaceutics8020016","volume":"8","author":"A Tuomela","year":"2016","unstructured":"Tuomela A, Hirvonen J, Peltonen L. Stabilizing agents for drug nanocrystals: effect on bioavailability. Pharmaceutics. 2016;8:16. https:\/\/doi.org\/10.3390\/pharmaceutics8020016.","journal-title":"Pharmaceutics"},{"key":"3322_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2025.100440","volume":"10","author":"J Siepmann","year":"2025","unstructured":"Siepmann J, Siepmann F. Release mechanisms of PLGA-based drug delivery systems: a review. International Journal of Pharmaceutics: X. 2025;10:100440. https:\/\/doi.org\/10.1016\/j.ijpx.2025.100440.","journal-title":"International Journal of Pharmaceutics: X"},{"key":"3322_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13195837","volume":"13","author":"M Jain","year":"2024","unstructured":"Jain M, Crites MK, Rich P, Bajantri B. Malignant pleural mesothelioma: a comprehensive review. J Clin Med. 2024;13:5837. https:\/\/doi.org\/10.3390\/jcm13195837.","journal-title":"J Clin Med"},{"key":"3322_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051134","volume":"10","author":"A Bellini","year":"2021","unstructured":"Bellini A, Dell\u2019Amore A, Terzi S, Zambello G, Zuin A, Pasello G, et al. Relapse patterns and tailored treatment strategies for malignant pleural mesothelioma recurrence after multimodality therapy. J Clin Med. 2021;10:1134. https:\/\/doi.org\/10.3390\/jcm10051134.","journal-title":"J Clin Med"},{"key":"3322_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093157","volume":"21","author":"M Krchniakova","year":"2020","unstructured":"Krchniakova M, Skoda J, Neradil J, Chlapek P, Veselska R. Repurposing tyrosine kinase inhibitors to overcome multidrug resistance in cancer: a focus on transporters and lysosomal sequestration. Int J Mol Sci. 2020;21:3157. https:\/\/doi.org\/10.3390\/ijms21093157.","journal-title":"Int J Mol Sci"},{"key":"3322_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.03.001","volume":"11","author":"S Salvi","year":"2016","unstructured":"Salvi S, Varesano S, Boccardo S, Ravetti JL, Canessa PA, Pistillo MP, et al. EGFR status in mesothelioma: possible implications for the efficacy of anti-EGFR and anti-MET therapies. J Thorac Oncol. 2016;11:e78\u2013e80. https:\/\/doi.org\/10.1016\/j.jtho.2016.03.001.","journal-title":"J Thorac Oncol"},{"key":"3322_CR51","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ctrv.2010.11.004","volume":"37","author":"V Agarwal","year":"2011","unstructured":"Agarwal V, Lind MJ, Cawkwell L. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand? Cancer Treat Rev. 2011;37:533\u201342. https:\/\/doi.org\/10.1016\/j.ctrv.2010.11.004.","journal-title":"Cancer Treat Rev"},{"key":"3322_CR52","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.bcp.2011.07.073","volume":"82","author":"F Barbieri","year":"2011","unstructured":"Barbieri F, W\u00fcrth R, Favoni RE, Pattarozzi A, Gatti M, Ratto A, et al. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1\/2 as antitumor targets. Biochem Pharmacol. 2011;82:1467\u201377. https:\/\/doi.org\/10.1016\/j.bcp.2011.07.073.","journal-title":"Biochem Pharmacol"},{"key":"3322_CR53","doi-asserted-by":"publisher","first-page":"14614","DOI":"10.1200\/jco.2008.26.15_suppl.14614","volume":"26","author":"CW Lee","year":"2008","unstructured":"Lee CW, Anderson H, Martins H, Rao SC, Sauciuc D, Laurie SA, et al. A phase II trial of gefitinib in patients with malignant pleural mesothelioma (MPM). JCO. 2008;26:14614\u201314614. https:\/\/doi.org\/10.1200\/jco.2008.26.15_suppl.14614.","journal-title":"JCO"},{"key":"3322_CR54","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11523-022-00883-0","volume":"17","author":"JE Frampton","year":"2022","unstructured":"Frampton JE. Osimertinib: a review in completely resected, early-stage, EGFR mutation-positive NSCLC. Target Oncol. 2022;17:369\u201376. https:\/\/doi.org\/10.1007\/s11523-022-00883-0.","journal-title":"Target Oncol"},{"key":"3322_CR55","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/LCTT.S119644","volume":"8","author":"M Santarpia","year":"2017","unstructured":"Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffin\u00e0 MG, D\u2019Aveni A, et al. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer (Auckl). 2017;8:109\u201325. https:\/\/doi.org\/10.2147\/LCTT.S119644.","journal-title":"Lung Cancer (Auckl)"},{"key":"3322_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121623","volume":"17","author":"VS de S\u00e3o Jos\u00e9","year":"2024","unstructured":"de S\u00e3o Jos\u00e9 VS, Vieira BM, Neto VM, Lima LM. Repurposing osimertinib and gedatolisib for glioblastoma treatment: evidence of synergistic effects in an in vitro phenotypic study. Pharmaceuticals. 2024;17:1623. https:\/\/doi.org\/10.3390\/ph17121623.","journal-title":"Pharmaceuticals"},{"key":"3322_CR57","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11095-020-02851-7","volume":"37","author":"E Weisberg","year":"2020","unstructured":"Weisberg E, Parent A, Yang PL, Sattler M, Liu Q, Liu Q, et al. Repurposing of kinase inhibitors for treatment of COVID-19. Pharm Res. 2020;37:167. https:\/\/doi.org\/10.1007\/s11095-020-02851-7.","journal-title":"Pharm Res"},{"key":"3322_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121623","volume":"17","author":"VS de S\u00e3o Jos\u00e9","year":"2024","unstructured":"de S\u00e3o Jos\u00e9 VS, Vieira BM, Neto VM, Lima LM. Repurposing osimertinib and gedatolisib for glioblastoma treatment: evidence of synergistic effects in an in vitro phenotypic study. Pharmaceuticals (Basel). 2024;17:1623. https:\/\/doi.org\/10.3390\/ph17121623.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3322_CR59","doi-asserted-by":"publisher","first-page":"23933","DOI":"10.1038\/s41598-021-03418-1","volume":"11","author":"AWY Chai","year":"2021","unstructured":"Chai AWY, Tan AC, Cheong SC. Uncovering drug repurposing candidates for head and neck cancers: insights from systematic pharmacogenomics data analysis. Sci Rep. 2021;11:23933. https:\/\/doi.org\/10.1038\/s41598-021-03418-1.","journal-title":"Sci Rep"},{"key":"3322_CR60","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.10.80","volume":"7","author":"I Chaib","year":"2019","unstructured":"Chaib I, Cai X, Llige D, Santarpia M, Jantus-Lewintre E, Filipska M, et al. Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma. Ann Transl Med. 2019;7:651. https:\/\/doi.org\/10.21037\/atm.2019.10.80.","journal-title":"Ann Transl Med"},{"key":"3322_CR61","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccell.2020.12.007","volume":"39","author":"C Huang","year":"2021","unstructured":"Huang C, Chen L, Savage SR, Eguez RV, Dou Y, Li Y, et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021;39:361-379.e16. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.007.","journal-title":"Cancer Cell"},{"key":"3322_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27625-0","volume":"13","author":"J Sforzi","year":"2023","unstructured":"Sforzi J, Lanfranco A, Stefania R, Alberti D, Bitonto V, Parisotto S, et al. A novel pH sensitive theranostic PLGA nanoparticle for boron neutron capture therapy in mesothelioma treatment. Sci Rep. 2023;13:620. https:\/\/doi.org\/10.1038\/s41598-023-27625-0.","journal-title":"Sci Rep"},{"key":"3322_CR63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejpb.2015.03.005","volume":"93","author":"L Mayol","year":"2015","unstructured":"Mayol L, Serri C, Menale C, Crispi S, Piccolo MT, Mita L, et al. Curcumin loaded PLGA-poloxamer blend nanoparticles induce cell cycle arrest in mesothelioma cells. Eur J Pharm Biopharm. 2015;93:37\u201345. https:\/\/doi.org\/10.1016\/j.ejpb.2015.03.005.","journal-title":"Eur J Pharm Biopharm"},{"key":"3322_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2023.101697","volume":"31","author":"M Sakhi","year":"2023","unstructured":"Sakhi M, Khan A, Khan I, Ahmad Khan S, Irum Khan S, Ali Khattak M, et al. Effect of polymeric stabilizers on the size and stability of PLGA paclitaxel nanoparticles. Saudi Pharm J. 2023;31:101697. https:\/\/doi.org\/10.1016\/j.jsps.2023.101697.","journal-title":"Saudi Pharm J"},{"key":"3322_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2019.109950","volume":"104","author":"P Rafiei","year":"2019","unstructured":"Rafiei P, Haddadi A. A robust systematic design: optimization and preparation of polymeric nanoparticles of PLGA for docetaxel intravenous delivery. Mater Sci Eng, C. 2019;104:109950. https:\/\/doi.org\/10.1016\/j.msec.2019.109950.","journal-title":"Mater Sci Eng, C"},{"key":"3322_CR66","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S2095-3119(19)62613-4","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Wang T. Preparation and characterization of atrazine-loaded biodegradable PLGA nanospheres. J Integr Agric. 2019;18:1035\u201341. https:\/\/doi.org\/10.1016\/S2095-3119(19)62613-4.","journal-title":"J Integr Agric"},{"key":"3322_CR67","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ijbiomac.2018.10.181","volume":"122","author":"B Vaidya","year":"2019","unstructured":"Vaidya B, Parvathaneni V, Kulkarni NS, Shukla SK, Damon JK, Sarode A, et al. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. Int J Biol Macromol. 2019;122:338\u201347. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.10.181.","journal-title":"Int J Biol Macromol"},{"key":"3322_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105615","volume":"95","author":"X Wang","year":"2024","unstructured":"Wang X, Goyal M, Gadhave D, Gupta V. Inhaled nintedanib nanoparticles for enhanced efficacy in idiopathic pulmonary fibrosis (IPF) treatment \u2013 evidence in disease-relevant in-vitro models. J Drug Deliv Sci Technol. 2024;95:105615. https:\/\/doi.org\/10.1016\/j.jddst.2024.105615.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3322_CR69","doi-asserted-by":"publisher","unstructured":"E. Rs, P. V, K. Ns, S. Sk, C. G, K. Nk, G. V, Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)-development and in-vitro efficacy, Drug Delivery and Translational Research 11 (2021). https:\/\/doi.org\/10.1007\/s13346-020-00802-8.","DOI":"10.1007\/s13346-020-00802-8"},{"key":"3322_CR70","unstructured":"Particle Engineering to Enhance Drug Delivery via Pulmonary Route of Administration - AAPS Newsmagazine, (n.d.). https:\/\/www.aapsnewsmagazine.org\/aapsnewsmagazine\/articles\/new-page3\/feb25\/cover-story-feb25b. Accessed 19 Feb 2025."},{"key":"3322_CR71","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.4155\/tde.15.37","volume":"6","author":"I d\u2019Angelo","year":"2015","unstructured":"d\u2019Angelo I, Quaglia F, Ungaro F. PLGA carriers for inhalation: where do we stand, where are we headed? Ther Deliv. 2015;6:1139\u201344. https:\/\/doi.org\/10.4155\/tde.15.37.","journal-title":"Ther Deliv"},{"key":"3322_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065204","volume":"24","author":"X Wang","year":"2023","unstructured":"Wang X, Chauhan G, Tacderas ARL, Muth A, Gupta V. Surface-modified inhaled microparticle-encapsulated celastrol for enhanced efficacy in malignant pleural mesothelioma. Int J Mol Sci. 2023;24:5204. https:\/\/doi.org\/10.3390\/ijms24065204.","journal-title":"Int J Mol Sci"},{"key":"3322_CR73","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.2147\/IJN.S269340","volume":"15","author":"WN Ibrahim","year":"2020","unstructured":"Ibrahim WN, Muizzuddin Bin Mohd Rosli L, Doolaanea AA. Formulation, cellular uptake and cytotoxicity of thymoquinone-loaded PLGA nanoparticles in malignant melanoma cancer cells. Int J Nanomedicine. 2020;15:8059\u201374. https:\/\/doi.org\/10.2147\/IJN.S269340.","journal-title":"Int J Nanomedicine"},{"key":"3322_CR74","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.9b00136","volume":"30","author":"A Tchoryk","year":"2019","unstructured":"Tchoryk A, Taresco V, Argent RH, Ashford M, Gellert PR, Stolnik S, et al. Penetration and uptake of nanoparticles in 3D tumor spheroids. Bioconjug Chem. 2019;30:1371\u201384. https:\/\/doi.org\/10.1021\/acs.bioconjchem.9b00136.","journal-title":"Bioconjug Chem"},{"key":"3322_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104305","volume":"81","author":"J Gupta","year":"2023","unstructured":"Gupta J, Quadros M, Momin M. Mesoporous silica nanoparticles: synthesis and multifaceted functionalization for controlled drug delivery. J Drug Deliv Sci Technol. 2023;81:104305. https:\/\/doi.org\/10.1016\/j.jddst.2023.104305.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3322_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121038","volume":"608","author":"V Parvathaneni","year":"2021","unstructured":"Parvathaneni V, Shukla SK, Kulkarni NS, Gupta V. Development and characterization of inhalable transferrin functionalized amodiaquine nanoparticles \u2013 efficacy in Non-Small Cell Lung Cancer (NSCLC) treatment. Int J Pharm. 2021;608:121038. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121038.","journal-title":"Int J Pharm"},{"key":"3322_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114315","volume":"200","author":"L Nie","year":"2024","unstructured":"Nie L, Zheng Z, Chen R, Liang S, Fu P, Wu S, et al. Novel erythrocyte-shaped electrosprayed nanoparticles for co-delivery of paclitaxel and osimertinib: preparation, characterization, and evaluation. Eur J Pharm Biopharm. 2024;200:114315. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114315.","journal-title":"Eur J Pharm Biopharm"},{"key":"3322_CR78","doi-asserted-by":"publisher","first-page":"A6563","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A6563","volume":"211","author":"M Quadros","year":"2025","unstructured":"Quadros M, Gupta V. Inhaled osimertinib for the treatment of malignant pleural mesothelioma. Am J Respir Crit Care Med. 2025;211:A6563\u2013A6563. https:\/\/doi.org\/10.1164\/ajrccm.2025.211.Abstracts.A6563.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03322-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03322-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03322-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:49:39Z","timestamp":1780390179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03322-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3322"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03322-1","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest. This work was presented as a conference abstract at the American Thoracic Society (ATS) 2025 International Conference and has been published as a peer-reviewed abstract [\n                      \n                      ]\n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"122"}}